Along with the comorbidities that come with those, many researchers started to focus on new biomarkers for diagnosing and staging PCa, evaluating them from the blood (PHI, 4Kscore, S3M), from urine (PCA3, TMPRSS2-ERG, TDRD1, DLX1, HOX6), or through radiographic modalities (multiparametric magnetic resonance imaging(mpMRI), multiparametric ultrasound (mpUS) [14,15]. This evidence concerns the gene PCA3 and posterior cortical atrophy.